Influenza Update

January 10, 2017
Overview

• Update on influenza-like-illness (ILI)
• Update on IHS influenza vaccine coverage
• Area Reports
U.S. Influenza Activity

• ILI activity has surpassed the national baseline of 2.2%
• Most activity so far has been caused by influenza A, H3N2 strain
• The 2016-2017 influenza vaccine is well-matched to circulating strains
• To date, in the U.S. there have been no influenza associated pediatric deaths
Percentage of Visits for Influenza-like Illness (ILI) Reported by the U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet), Weekly National Summary, 2016-2017 and Selected Previous Seasons
Weekly Influenza Activity Estimates Reported by State & Territorial Epidemiologists*
Week ending December 31, 2016 - Week 52

* This map indicates geographic spread & does not measure the severity of influenza activity.
FLUVIEW
A Weekly Influenza Surveillance Report Prepared by the Influenza Division

Pneumonia and Influenza Mortality from the National Center for Health Statistics Mortality Surveillance System
Data through the week ending December 17, 2016, as of January 4, 2017

% of All Deaths Due to P&I

Epidemic Threshold
Seasonal Baseline

MMWR Week

40 50 10 20 30 40 10 20 30 40 50 10 20 30 40 50
U.S. Influenza Vaccine Supply

• Influenza vaccine supply:
  – Projected: 157 million - 168 million doses

• Distributed doses as of 12/30/16:
  – 143.7 million doses
U.S. Influenza Vaccine Coverage

• Early season flu vaccination coverage, United States, November 2016*
  – Children (6 mon. – 17 years) – 37.3%
  – Adults (18 years and older) – 40.6%
  – All (6 mon. and older) – 39.8%

• Early season Healthcare Personnel flu vaccine coverage, United States, November 2016†
  – 68.5%

*End-of-season estimates are from the National Immunization Survey-Flu for children (6 months through 17 years) and the Behavioral Risk Factor Surveillance System for adults (18 years and older) (https://www.cdc.gov/flu/fluvaxview/nifs-estimates-nov2016.htm).
† HCP vaccination coverage based on data from the National Health Interview Survey (NHIS), the data source used to monitor the Healthy People 2020 objective, was 68.6% in the 2014–15 flu season (18). The methods used in the Internet panel survey differ from those of the NHIS; thus, results from the Internet panel survey should not be directly compared to the Healthy People 2020 target.
IHS Influenza Awareness System
as of 12/31/2016

• Influenza-like-illness (ILI) activity is beginning to increase across a majority of IHS Regions

• ~276,000 doses of influenza vaccine have been administered in IHS

• Weekly IIAS reports now available on the IHS Flu Website
  – www.ihs.gov/flu
IHS ILI Activity as of 12/31/2016

% of outpatient visits for influenza-like-illness (ILI)

Source: IAS ILINet
All IHS Areas
Influenza-Like Illness (ILI) for All Surveillance Years
Percentage of Visits for ILI per week
01/04/09 to 12/31/2016
IHS INFLUENZA VACCINE COVERAGE

Week 52
## Influenza Vaccination Coverage by Age Group*

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Active Clinical Population**</th>
<th>Seasonal Flu Vaccine (At Least 1 Dose)***</th>
<th>% Seasonal Flu (At Least 1 Dose)</th>
<th>Seasonal Flu Vaccine (At Least 2 Doses)</th>
<th>% Seasonal Flu (At Least 2 Doses)</th>
<th>Total #Doses Administered****</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 - 5 months</td>
<td>4,398</td>
<td>37</td>
<td>0.8</td>
<td>0</td>
<td>0.0</td>
<td>38</td>
</tr>
<tr>
<td>6 - 23 months</td>
<td>21,343</td>
<td>9,327</td>
<td>43.7</td>
<td>1,566</td>
<td>7.3</td>
<td>10,951</td>
</tr>
<tr>
<td>2 - 4 years</td>
<td>52,466</td>
<td>12,481</td>
<td>23.8</td>
<td>240</td>
<td>0.5</td>
<td>12,815</td>
</tr>
<tr>
<td>5 - 17 years</td>
<td>197,398</td>
<td>55,199</td>
<td>28.0</td>
<td>327</td>
<td>0.2</td>
<td>55,911</td>
</tr>
<tr>
<td>18 - 49 years</td>
<td>402,484</td>
<td>90,369</td>
<td>22.5</td>
<td>402</td>
<td>0.1</td>
<td>91,549</td>
</tr>
<tr>
<td>50 - 64 years</td>
<td>169,096</td>
<td>61,142</td>
<td>36.2</td>
<td>343</td>
<td>0.2</td>
<td>62,053</td>
</tr>
<tr>
<td>65 + years</td>
<td>97,000</td>
<td>42,661</td>
<td>44.0</td>
<td>289</td>
<td>0.3</td>
<td>43,394</td>
</tr>
<tr>
<td>Children (6 months-17 years)</td>
<td>271,207</td>
<td>77,007</td>
<td>28.4</td>
<td>2,133</td>
<td>0.8</td>
<td>79,677</td>
</tr>
<tr>
<td>Adults (18 + years)</td>
<td>668,580</td>
<td>194,172</td>
<td>29.0</td>
<td>1,034</td>
<td>0.2</td>
<td>196,996</td>
</tr>
<tr>
<td>All (6 months +)</td>
<td>939,787</td>
<td>271,179</td>
<td>28.9</td>
<td>3,167</td>
<td>0.3</td>
<td>276,673</td>
</tr>
</tbody>
</table>
Influenza Vaccine Coverage as of 12/31/2016
Influenza Vaccine Coverage
Week 52
2015-16 vs. 2016-2017

Influenza Vaccine Coverage

Alaska  ABQ  BEM  BIL  CAO  GPA  NAV  NSA  OCA  PHX  POR  TUC  ALL

2015-2016  2016-2017
<table>
<thead>
<tr>
<th>Area</th>
<th>INACTIV E CVX CODES</th>
<th>CVX 88 FLU-NOS**</th>
<th>CVX 111 FLU-LAIV3</th>
<th>CVX 135 FLU-HIGH</th>
<th>CVX 140 FLU-LIIV3</th>
<th>CVX 141 FLU-LIIV3</th>
<th>CVX 144 FLU-DERMAL</th>
<th>CVX 149 FLU-LAIIV4</th>
<th>CVX 150 FLU-LIIV4pf</th>
<th>CVX 153 FLU-CILLIIV3</th>
<th>CVX 155 FLU-RIV3</th>
<th>CVX 158 IIV4</th>
<th>CVX 161 IIV4pf -ped</th>
<th>CVX 166</th>
<th>Proc 99.52 Vac Inf</th>
<th>ICD-9 V04.8</th>
<th>ICD-9 V06.6</th>
<th>CPT Billing Codes+</th>
<th>Cumulative # of Doses Seasonal Flu</th>
</tr>
</thead>
<tbody>
<tr>
<td>AK</td>
<td>3</td>
<td>238</td>
<td>0</td>
<td>394</td>
<td>39</td>
<td>548</td>
<td>1</td>
<td>0</td>
<td>5152</td>
<td>0</td>
<td>2</td>
<td>3120</td>
<td>375</td>
<td>19</td>
<td>0</td>
<td>0</td>
<td>47</td>
<td>9938</td>
<td></td>
</tr>
<tr>
<td>ALB</td>
<td>1</td>
<td>158</td>
<td>0</td>
<td>1256</td>
<td>521</td>
<td>9358</td>
<td>1</td>
<td>0</td>
<td>4274</td>
<td>0</td>
<td>6</td>
<td>1907</td>
<td>583</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>80</td>
<td>18146</td>
<td></td>
</tr>
<tr>
<td>BEM</td>
<td>264</td>
<td>82</td>
<td>0</td>
<td>374</td>
<td>9</td>
<td>2020</td>
<td>0</td>
<td>1</td>
<td>3479</td>
<td>5</td>
<td>4</td>
<td>3272</td>
<td>229</td>
<td>41</td>
<td>0</td>
<td>1</td>
<td>158</td>
<td>9939</td>
<td></td>
</tr>
<tr>
<td>BIL</td>
<td>5</td>
<td>231</td>
<td>0</td>
<td>882</td>
<td>12</td>
<td>2090</td>
<td>0</td>
<td>0</td>
<td>9647</td>
<td>0</td>
<td>0</td>
<td>1631</td>
<td>848</td>
<td>141</td>
<td>0</td>
<td>0</td>
<td>110</td>
<td>15597</td>
<td></td>
</tr>
<tr>
<td>CA</td>
<td>12</td>
<td>176</td>
<td>0</td>
<td>1320</td>
<td>20</td>
<td>2548</td>
<td>1</td>
<td>7</td>
<td>7692</td>
<td>0</td>
<td>2</td>
<td>4490</td>
<td>1296</td>
<td>59</td>
<td>0</td>
<td>2</td>
<td>111</td>
<td>17736</td>
<td></td>
</tr>
<tr>
<td>GPA</td>
<td>3</td>
<td>391</td>
<td>0</td>
<td>1029</td>
<td>137</td>
<td>11670</td>
<td>0</td>
<td>0</td>
<td>11386</td>
<td>12</td>
<td>26</td>
<td>5150</td>
<td>963</td>
<td>9</td>
<td>0</td>
<td>0</td>
<td>87</td>
<td>30863</td>
<td></td>
</tr>
<tr>
<td>NSA</td>
<td>200</td>
<td>329</td>
<td>0</td>
<td>349</td>
<td>115</td>
<td>5181</td>
<td>213</td>
<td>0</td>
<td>3816</td>
<td>4</td>
<td>18</td>
<td>340</td>
<td>131</td>
<td>316</td>
<td>0</td>
<td>0</td>
<td>113</td>
<td>11125</td>
<td></td>
</tr>
<tr>
<td>NAV</td>
<td>24</td>
<td>299</td>
<td>1</td>
<td>1720</td>
<td>20</td>
<td>9367</td>
<td>9</td>
<td>0</td>
<td>11829</td>
<td>0</td>
<td>1</td>
<td>39134</td>
<td>2369</td>
<td>1023</td>
<td>0</td>
<td>0</td>
<td>167</td>
<td>65963</td>
<td></td>
</tr>
<tr>
<td>OK</td>
<td>254</td>
<td>1761</td>
<td>1</td>
<td>2361</td>
<td>11</td>
<td>25198</td>
<td>7</td>
<td>1</td>
<td>8175</td>
<td>1</td>
<td>13</td>
<td>2189</td>
<td>1281</td>
<td>531</td>
<td>0</td>
<td>0</td>
<td>215</td>
<td>41998</td>
<td></td>
</tr>
<tr>
<td>PHX</td>
<td>2</td>
<td>451</td>
<td>0</td>
<td>1142</td>
<td>27</td>
<td>8261</td>
<td>12</td>
<td>0</td>
<td>18014</td>
<td>0</td>
<td>19</td>
<td>404</td>
<td>1861</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>232</td>
<td>30426</td>
<td></td>
</tr>
<tr>
<td>POR</td>
<td>8</td>
<td>351</td>
<td>1</td>
<td>709</td>
<td>1142</td>
<td>7562</td>
<td>10</td>
<td>1</td>
<td>4632</td>
<td>28</td>
<td>19</td>
<td>2942</td>
<td>305</td>
<td>1106</td>
<td>0</td>
<td>0</td>
<td>756</td>
<td>19572</td>
<td></td>
</tr>
<tr>
<td>TUC</td>
<td>0</td>
<td>46</td>
<td>0</td>
<td>28</td>
<td>24</td>
<td>8</td>
<td>0</td>
<td>0</td>
<td>5788</td>
<td>1</td>
<td>0</td>
<td>34</td>
<td>369</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>36</td>
<td>6334</td>
<td></td>
</tr>
<tr>
<td>HQ</td>
<td>0</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>776</strong></td>
<td><strong>4515</strong></td>
<td><strong>2</strong></td>
<td><strong>11564</strong></td>
<td><strong>2077</strong></td>
<td><strong>83811</strong></td>
<td><strong>254</strong></td>
<td><strong>10</strong></td>
<td><strong>93884</strong></td>
<td><strong>51</strong></td>
<td><strong>110</strong></td>
<td><strong>64613</strong></td>
<td><strong>10610</strong></td>
<td><strong>3247</strong></td>
<td><strong>0</strong></td>
<td><strong>3</strong></td>
<td><strong>2112</strong></td>
<td><strong>277639</strong></td>
<td></td>
</tr>
</tbody>
</table>

* Inactive CVX Codes 15 (FLU-TIVhx), 16 (FLU-WHOLE), 123 (FLU-H5N1), and 151 (FLU-NasNOS) should not be used to document flu vaccines given this flu season. Doses are NOT deduplicated.
** CVX Code 88 (FLU-NOS) should only be used to document flu vaccines given elsewhere when flu vaccine type is unknown.
+ CPT Flu codes include: 90654-90662, 90672-90673, 90685-90686, 90724, G0008, G8108.
^ ICD9 codes V04.8 and V06.6 are not displayed on this report and are not used in any of the influenza vaccine coverage calculations.
Summary

• Influenza is increasing across the country
• Seasonal influenza vaccine appears to be well matched to circulating strains
• It’s not too late to get vaccinated
  – Less than 1/3 of the IHS patient population has received an influenza vaccine